| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000409306 |
| ISSN: | 1665-2681 |
| Autores: | Rezaee-Zavareh, Mohammad S1 Hesamizadeh, Khashayar1 Behnava, Bita1 Alavian, Seyed M1 Gholami-Fesharaki, Mohammad2 Sharafi, Heidar1 |
| Instituciones: | 1Baqiyatallah University of Medical Sciences, Teherán. Irán 2Tarbiat Modares University, Faculty of Medical Sciences, Teherán. Irán |
| Año: | 2017 |
| Periodo: | Mar-Abr |
| Volumen: | 16 |
| Número: | 2 |
| Paginación: | 188-197 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Revisión bibliográfica |
| Enfoque: | Analítico |
| Resumen en inglés | Combination of Sofosbuvir (SOF) and Ledipasvir (LDV) has been lead to considerable enhancement of treatment of hepatitis C virus (HCV) genotype 1 infection. A meta-analysis of the currently available studies was undertaken with the aim to evaluate the antiviral efficacy of SOF/LDV therapy for 12 or 24 weeks with or without Ribavirin (RBV) in patients with HCV genotype 1 infection. Material and methods. Material and methods. In Material and methods. this meta-analysis, we searched databases including PubMed, Scopus, Science Direct and Web of Science using appropriate keywords. All papers which evaluated the efficacy of combination therapy of SOF/LDV with or without RBV for 12 or 24 weeks among patients with HCV genotype 1 infection were included. Results. Results. The 20 Results. published articles were assessed for eligibility and finally 10 articles pooling 2248 participants were included in this meta-analysis. Pooled SVR12 for four SOF/LDV regimens were 95% (95%CI = 93%-97%) for 12 weeks of treatment with SOF/LDV, 97% (95%CI = 95%-98%) for 24 weeks of treatment with SOF/LDV, 96% (95%CI = 94%-97%) for 12 weeks of treatment with SOF/ LDV/RBV and 98% (95%CI = 97%-99%) for 24 weeks of treatment with SOF/LDV/RBV. Only in treatment regimen of SOF/LDV for 12 weeks, cirrhosis had a significant effect on the SVR12 (OR = 0.21, 95%CI = 0.07-0.66). Furthermore, NS5A resistance-associated substitutions at baseline were associated with decrease in the rate of SVR (OR = 0.31, 95%CI = 0.2-0.5). Conclusions. Conclusions. The Interferon-free regimen of SOF/LDV for 12 or 24 weeks with or without RBV is highly effective for treatment of patients with HCV genotype 1 infection |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Microbiología, Terapéutica y rehabilitación, Hepatitis C, Genotipos, Sofosbuvir, Ledipasvir, Meta-análisis |
| Keyword: | Medicine, Gastroenterology, Microbiology, Therapeutics and rehabilitation, Hepatitis C, Genotypes, Sofosbuvir, Ledipasvir, Meta-analysis |
| Texto completo: | Texto completo (Ver PDF) |
